MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD)
· seekingalpha.com
MannKind’s Afrezza wins FDA approval for pediatric use—unlocking growth and a $300–500M opportunity. Read here for more on MNKD stock.
As you know, MannKind ( MNKD ) has just seen the approval of Afrezza by the FDA. Now, the way I see it is that this is a pretty meaningful expansion of an alrea...